Thymosin beta4, inhibitor for normal hematopoietic progenitor cells.

Bonnet D, Lemoine FM, Frobert Y, Bonnet ML, Baillou C, Najman A, Guigon M

Experimental hematology1 Jun 1996Cited by 27 (Europe PMC)

PMID8647227PepBankPUB-08647227

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Efficacy outcome
Thymosin beta4 inhibited the growth of normal human bone marrow progenitor cells.
In plain wordsIn human cells in the lab, thymosin beta4 slowed the growth of normal bone marrow progenitor cells.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseGrowth of normal bone marrow progenitor cells
Study
humann: not reported in source
human bone marrow progenitor cells
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
We demonstrate that it inhibits normal bone marrow progenitor cell growth
1 context sentence(design, population, supporting numbers)
Summary · context
Because it contains at its N-terminal end the sequence of a known inhibitor of hematopoiesis, the acetylated tetrapeptide Ac-N-Ser-Asp-Lys-Pro (AcSDKP, Goralatide), we have assayed Tbeta4 on human hematopoietic cells.
Report a problemFND-0864722701
02LabIn vitro (cells)Efficacy outcome
Thymosin beta4 decreased the growth of granulo-macrophagic progenitors.
In plain wordsIn human cells in the lab, thymosin beta4 slowed the growth of one type of blood progenitor cell.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseGrowth of granulo-macrophagic progenitors
Study
humann: not reported in source
human bone marrow progenitor cells
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
indeed, it decreased the growth of both granulo-macrophagic and erythroid progenitors and reduces their percentage in S phase.
1 context sentence(design, population, supporting numbers)
Summary · context
Because it contains at its N-terminal end the sequence of a known inhibitor of hematopoiesis, the acetylated tetrapeptide Ac-N-Ser-Asp-Lys-Pro (AcSDKP, Goralatide), we have assayed Tbeta4 on human hematopoietic cells.
Report a problemFND-0864722702
03LabIn vitro (cells)Efficacy outcome
Thymosin beta4 decreased the growth of erythroid progenitors.
In plain wordsIn human cells in the lab, thymosin beta4 slowed the growth of red blood cell progenitors.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseGrowth of erythroid progenitors
Study
humann: not reported in source
human bone marrow progenitor cells
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
indeed, it decreased the growth of both granulo-macrophagic and erythroid progenitors and reduces their percentage in S phase.
1 context sentence(design, population, supporting numbers)
Summary · context
Because it contains at its N-terminal end the sequence of a known inhibitor of hematopoiesis, the acetylated tetrapeptide Ac-N-Ser-Asp-Lys-Pro (AcSDKP, Goralatide), we have assayed Tbeta4 on human hematopoietic cells.
Report a problemFND-0864722703
04LabIn vitro (cells)Efficacy outcome
Thymosin beta4 reduced the percentage of progenitor cells in S phase.
In plain wordsIn human cells in the lab, thymosin beta4 reduced the share of progenitor cells that were copying their DNA.
Peptide
Thymosin beta-4 (human)
Outcome
DecreasePercentage of progenitors in S phase
Study
humann: not reported in source
human bone marrow progenitor cells
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
and reduces their percentage in S phase.
1 context sentence(design, population, supporting numbers)
Summary · context
Because it contains at its N-terminal end the sequence of a known inhibitor of hematopoiesis, the acetylated tetrapeptide Ac-N-Ser-Asp-Lys-Pro (AcSDKP, Goralatide), we have assayed Tbeta4 on human hematopoietic cells.
Report a problemFND-0864722704
05LabIn vitro (cells)Efficacy outcome
Thymosin beta4 reduced the clonogenicity of purified CD34+ cells induced by a combination of seven growth factors.
In plain wordsIn human cells in the lab, thymosin beta4 reduced colony formation by CD34+ blood stem cells that growth factors had stimulated.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseClonogenicity of purified CD34+ cells
Study
humann: not reported in source
human bone marrow progenitor cells
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
Furthermore, we show that Tbeta4 reduces both the clonogenicity and the cell proliferation of purified CD34+ cells induced by a combination of seven growth factors.
1 context sentence(design, population, supporting numbers)
Summary · context
Because it contains at its N-terminal end the sequence of a known inhibitor of hematopoiesis, the acetylated tetrapeptide Ac-N-Ser-Asp-Lys-Pro (AcSDKP, Goralatide), we have assayed Tbeta4 on human hematopoietic cells.
Report a problemFND-0864722705
06LabIn vitro (cells)Efficacy outcome
Thymosin beta4 reduced the cell proliferation of purified CD34+ cells induced by a combination of seven growth factors.
In plain wordsIn human cells in the lab, thymosin beta4 reduced the growth of CD34+ blood stem cells that growth factors had stimulated.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseCell proliferation of purified CD34+ cells
Study
humann: not reported in source
human bone marrow progenitor cells
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
Furthermore, we show that Tbeta4 reduces both the clonogenicity and the cell proliferation of purified CD34+ cells induced by a combination of seven growth factors.
1 context sentence(design, population, supporting numbers)
Summary · context
Because it contains at its N-terminal end the sequence of a known inhibitor of hematopoiesis, the acetylated tetrapeptide Ac-N-Ser-Asp-Lys-Pro (AcSDKP, Goralatide), we have assayed Tbeta4 on human hematopoietic cells.
Report a problemFND-0864722706
07LabIn vitro (cells)Mechanism
Neutralizing antibodies and a truncated form of thymosin beta4 without the AcSDKP sequence showed that the inhibitory effect of thymosin beta4 is not mediated by the AcSDKP sequence.
In plain wordsIn human cells in the lab, the slowing of progenitor growth did not depend on the AcSDKP part of thymosin beta4.
Peptide
Thymosin beta-4 (human)
Outcome
Not applicableRole of the AcSDKP sequence in the inhibitory effect
Study
humann: not reported in source
human bone marrow progenitor cells
Outcome group
Receptor activity and mechanism · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
Although Tbeta4's inhibitory effect is very similar to that of AcSDKP, we demonstrate, using neutralizing antibodies and a truncated form of Tbeta4 devoid of the AcSDKP sequence, that the inhibitory effect of Tbeta4 is not mediated by the sequence AcSDKP.
1 context sentence(design, population, supporting numbers)
Summary · context
Because it contains at its N-terminal end the sequence of a known inhibitor of hematopoiesis, the acetylated tetrapeptide Ac-N-Ser-Asp-Lys-Pro (AcSDKP, Goralatide), we have assayed Tbeta4 on human hematopoietic cells.
Report a problemFND-0864722707

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 01:52 UTC
Study results updated
Version 1
12 Oct 2026, 18:17 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.